Document is current
Any future updates will be listed below
-
Authors
Sayin, Sama I.
Eklund, Ella A.
Beischer, Moa
Moe, Torill
Ali, Kevin X.
Gunnarsson, Kerstin
Xylander, Moe
Ny, Lars
Jakola, Asgeir S.
Häggström, Ida
Wiel, Clotilde
Hallqvist, Andreas
Sayin, Volkan I.
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 11 June 2025
Accepted: 27 November 2025
First Online: 11 December 2025
Declarations
:
: Approval from the Swedish Ethical Review Authority (Dnr 2019–04771 and 2021–04987) was obtained prior to the commencement of the study. The study was conducted in accordance with the ethical standards of the Swedish Ethical Review Authority and the 1964 Helsinki declaration. No informed consent was required due to all data being presented in a de-identified form according to the Swedish Ethical Review Authority.
: Not applicable. Patient consent statements were not required due to the retrospective nature of this study.
: LN has received lecturing honoraria from Bristol Myers Squibb, Immunocore, Miltenyi Biotec, MSD, Novartis, Pierre Fabre and Roche. LN has participated in advisory board meetings with Bristol Myers Squibb, MSD, Novartis, and Pierre Fabre. LN has stocks/ownership in SATMEG Ventures. EAE has received lecturing honoraria from AstraZeneca. AH has received lecturing honoraria from AstraZeneca.
